Lv1
18 积分 2026-06-26 加入
Discovery of Daraxonrasib (RMC-6236), a Potent and Orally Bioavailable RAS(ON) Multi-selective, Noncovalent Tri-complex Inhibitor for the Treatment of Patients with Multiple RAS-Addicted Cancers
2天前
已完结
Daraxonrasib for Previously Treated RAS -Mutant Non–Small-Cell Lung Cancer
1个月前
已完结
BRD4: From molecular understanding to therapeutics development
2个月前
已完结
Tumor-Targeted Delivery of an EGFR Inhibitor Prodrug via Site-Specific Albumin Conjugation
3个月前
已完结
A β‐Glucuronidase‐Responsive Albumin‐Binding Prodrug of a Potent Focal Adhesion Kinase Inhibitor for Targeted Cancer Therapy
3个月前
已完结
皖公网安备34019202002308
